ArticleInnovations in pharmacy2021
Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure.
Article in Innovations in pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Towards the Improvement of Patient Experience Evaluation Items for Patient-Centered Care in Head and Neck Cancer: A Qualitative Comparative Study.Healthcare (Basel, Switzerland) · 2024Article
- Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.Innovations in pharmacy · 2023Article
- Rejecting False Claims from Markov Simulations in Alzheimer's Disease.Innovations in pharmacy · 2023Article
- Evidentiary Standards for Patient-Centered Core Impact (PC-CIS) Value Claims.Innovations in pharmacy · 2022Article
- Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22.F1000Research · 2022Article
- Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.Innovations in pharmacy · 2022Article
- Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).Innovations in pharmacy · 2022Article
- Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.Innovations in pharmacy · 2022Article
- Rasch Measurement and Patient Reported Value Claims: A Primer for Hemophilia.Innovations in pharmacy · 2022Article
- A critical review of the definition of 'wellbeing' for doctors and their patients in a post Covid-19 era.The International journal of social psychiatry · 2021Review
- Abandoning Eugenics and the QALY.Innovations in pharmacy · 2021Article
- Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment.Innovations in pharmacy · 2021Article
- Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce.Innovations in pharmacy · 2021Article
- A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.Innovations in pharmacy · 2021Article
- A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.Innovations in pharmacy · 2021Article
- Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.Innovations in pharmacy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quality adjusted life year (QALY) has serious problems related to its failure to adhere to measurement theory. If a QALY is to be meaningful, the utility score that translates time spent to an equivalent time spent in so-called perfect health must have ratio properties (i.e., it must support multiplication). Multiattribute utility scores (e.g. those generated by the EQ-5D-5L) fail to meet this standard. The multiattribute instruments produce ordinal scores that lack a true zero and they generate negative values. The manifest deficiencies of multiattribute utility instruments render them unfit, not only as a measure of therapy response but also in generating QALY claims. After 30 years of belief in their use, utilities and QALYs are clearly analytical dead ends. The purpose of this commentary is to demonstrate a coherent way forward in health technology assessment by focusing, not on clinical attributes as surrogates for quality of life, but on measures that are based on a conceptual model describing patient value in terms of need-fulfilment. Building on an extensive, yet often overlooked literature, need-based measures that fit Rasch Measurement Theory criteria are converted from ordinal scores to interval scores to evaluate response to therapy. These measures meet the requirements of single attribute fundamental measurement which is the standard in the physical sciences. It is proposed that a translation from a Rasch interval scale (defined by logits) can be transformed to a bounded ratio scale. Need based Quality of Life (N-QOL) scales bounded by 0 (where no needs are fulfilled) to 1 (where all needs are fulfilled) form such scales. The N-QOL supports the full range of arithmetic operations. Multiattribute utilities and mathematically invalid QALYs can be put to one side as unfortunate historical curiosities in favor of a disease or target population specific N-QOL scale. Such a scale has the required properties to evaluate disease specific response to therapy This can also support N-QOL adjusted life years with a need- fulfillment life year (NALY) metric with ratio properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.